Fouad Namouni
Independent DirectorDr. Fouad Namouni, M.D. is Director of Vor Biopharma Inc. since May 2024. He serves as the President of Research and Development at Blueprint Medicines Corporation since September 1, 2020. He had been Independent Director of Aprea Therapeutics, Inc. since June 30, 2020 until May 16, 2022 and serves as Director at Aprea Therapeutics AB since July 2020. Dr. Namouni had been the Head of Oncology Development at Bristol Myers Squibb Company from August 2016 to April 2020. He has over two decades of experience in clinical development, regulatory affairs and medical affairs within the biotechnology and pharmaceutical industries. Dr. Namouni joined Bristol Myers Squibb in France in 1999 as Life Cycle Manager for Taxol and has held positions of increasing responsibility in R&D since. Dr. Namouni moved to the U.S. in September 2006 where he became responsible for the development of Erbitux. Previously, he served as head of global medical affairs from September 2015 to September 2017 and head of development for Opdivo (nivolumab) and Yervoy (ipilimumab) from January 2011 to September 2015. Earlier in his career, Dr. Namouni was a Pediatric Oncologist at Institut Curie in Paris where his focus was clinical research for the treatment of pediatric tumors. He received his medical degree from the University of Annaba Medical School in Algeria and his Pediatrics degree from Université Rene Descartes in Paris, France. He also received his Pediatric Oncology and Hematology degree and M.S. in Clinical and Experimental Pharmacology from Université Paris Sud in France.
公司职务
- 公司名称Vor Biopharma Inc.股票代码VOR职务Independent Director共事同僚
- JKJean-Paul KressChairman, President & CEO
- SMSandesh MahatmeChief Business Officer & CFO
- RYRobert Yuen Lee AngStrategic Advisor
- SMSiddhartha MukherjeeScientific Founder & Chairman of Scientific Advisory Board
- AOAdi OsovskyGeneral Counsel
- DBDaniella BeckmanLead Independent Director
- AGAlexander G. CumboIndependent Director
